Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Respir J ; 26(3): 487-93, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16135733

ABSTRACT

Chronic increased pulmonary blood flow is considered a pre-requisite for the induction of advanced vascular lesions in pulmonary arterial hypertension in congenital heart defects. The aim of the present study was to characterise the effects of increased pulmonary flow induced by an aortocaval shunt in the monocrotaline rat model for pulmonary hypertension in terms of survival, haemodynamics, pathology and histology. Male Wistar rats were injected with monocrotaline followed by the creation of an abdominal aortocaval shunt. Animals were sacrificed when displaying symptoms of weight loss or dyspnoea, 4-5 weeks after the creation of the shunt. Echocardiography identified increased ventricular dimensions in shunted rats and right ventricular hypertrophy in monocrotaline-treated rats. At similar pulmonary artery pressures, shunted monocrotaline rats displayed higher morbidity and mortality, increased pulmonary-to-systemic artery pressure ratios and increased right ventricular hypertrophy compared with nonshunted monocrotaline rats. Histological assessment demonstrated increased number and diameter of pre-acinar pulmonary arteries. Intra-acinar vessel remodelling and occlusion occurred to a similar extent in shunted and nonshunted monocrotaline rats. In conclusion, increased pulmonary blood flow in monocrotaline-induced pulmonary hypertension is associated with increased morbidity, mortality, and unfavourable haemodynamic and cardiac effects. These effects could be attributed to more pronounced right heart failure rather than to altered intra-acinar pulmonary vessel remodelling.


Subject(s)
Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/physiopathology , Pulmonary Circulation/physiology , Animals , Blood Pressure/physiology , Disease Models, Animal , Heart Atria/pathology , Heart Bypass, Right , Heart Valves/diagnostic imaging , Heart Valves/pathology , Hypertension, Pulmonary/etiology , Lung/pathology , Male , Monocrotaline , Pulmonary Artery/pathology , Rats , Rats, Wistar , Ultrasonography
2.
Eur J Clin Invest ; 34(9): 631-40, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15379763

ABSTRACT

BACKGROUND: The capsular polysaccharide glucuronoxylomannan (GXM) of Cryptococcus neoformans interferes with the chemotaxis and transendothelial migration of neutrophils. Intravenous administration of purified GXM has been shown to reduce the influx of inflammatory cells in an animal model of bacterial infection. Here we show that isolated GXM can also interfere with neutrophil migration in a model of inflammation not related to infection. We assessed the effects of intravenous GXM on neutrophil infiltration in a rat model of myocardial ischaemia, where neutrophil infiltration has been shown to contribute to postischaemic reperfusion injury. MATERIALS AND METHODS: Rats were subjected to coronary artery ligation followed by a 3-h reperfusion period. Myeloperoxidase-activity was measured in the ischaemic tissues as a marker of neutrophil infiltration. RESULTS: Intravenous administration of GXM markedly reduced the influx of neutrophils in the ischaemic myocardium as measured by a 65% reduction of tissue MPO activity. This reduction of MPO activity was clearly correlated to the serum concentration of GXM. As complement activation by GXM was minimal at the doses applied in vivo, it is unlikely that generation of chemotactic C5a in the circulation by GXM caused the observed reduction in leucocyte migration. CONCLUSION: Purified cryptococcal GXM has the ability to reduce neutrophil influx even outside the scope of infection.


Subject(s)
Myocardial Ischemia/immunology , Neutrophils/immunology , Polysaccharides/pharmacology , Animals , Complement C5/immunology , Coronary Vessels , Cryptococcosis/immunology , Cryptococcus neoformans , Ligation , Male , Rats , Rats, Wistar
3.
Am J Physiol Heart Circ Physiol ; 281(6): H2590-6, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11709427

ABSTRACT

To investigate the functional consequences of postinfarct cardiac angiotensin (ANG) type 2 (AT(2)) receptor upregulation, rats underwent coronary artery ligation or sham operation and were infused with ANG II 3-4 wk later, when scar formation is complete. ANG II increased mean arterial pressure (MAP) more modestly in infarcted animals than in sham animals. The AT(1) receptor antagonist irbesartan, but not the AT(2) receptor antagonist PD123319, decreased MAP and antagonized the ANG II-mediated systemic hemodynamic effects. Myocardial (MVC) but not renal vascular conductance (RVC) was diminished in infarcted versus sham rats. ANG II did not affect MVC and reduced RVC in all rats. MVC was unaffected by irbesartan and PD123319 in all animals. However, with PD123319, ANG II reduced MVC in sham but not infarcted animals, and, with irbesartan, ANG II increased MVC in infarcted but not sham animals. Irbesartan increased RVC and antagonized the ANG II-mediated renal effects in all animals. RVC, at baseline or with ANG II, was not affected by PD123319 in infarcted and sham animals. In conclusion, coronary but not renal AT(2) receptor stimulation results in vasodilation, and this effect is enhanced in infarcted rats.


Subject(s)
Coronary Circulation/physiology , Myocardial Infarction/metabolism , Receptors, Angiotensin/metabolism , Vasodilation/physiology , Angiotensin II/pharmacology , Animals , Antihypertensive Agents/pharmacology , Biphenyl Compounds/pharmacology , Cardiac Output/drug effects , Cardiac Output/physiology , Coronary Circulation/drug effects , Heart Failure/metabolism , Heart Rate/drug effects , Heart Rate/physiology , Imidazoles/pharmacology , Irbesartan , Male , Myocardial Infarction/mortality , Pyridines/pharmacology , Rats , Rats, Wistar , Receptor, Angiotensin, Type 2 , Renal Circulation/drug effects , Renal Circulation/physiology , Survival Rate , Tetrazoles/pharmacology , Vasoconstriction/drug effects , Vasoconstriction/physiology , Vasoconstrictor Agents/pharmacology , Vasodilation/drug effects
4.
Eur J Pharmacol ; 423(2-3): 195-202, 2001 Jul 06.
Article in English | MEDLINE | ID: mdl-11448485

ABSTRACT

Acute myocardial infarction evokes activation of, among others, the arginine-vasopressin system, resulting in vasoconstriction and fluid retention. In the present study, the vasoconstrictor and antidiuretic effects of vasopressin were examined in vivo in conscious rats with chronic myocardial infarction, in the absence or presence of the V(1a) receptor antagonist SR-49059 or the V(2) receptor antagonist OPC-31260. In sham rats, vasopressin dose-dependently increased mean arterial pressure (maximum response: 45+/-3 mm Hg), which was significantly suppressed in infarcted rats (maximum response: 32+/-3 mm Hg). SR-49059, but not OPC-31260, caused a significant rightward shift of the dose pressure response curve in sham rats, indicating V(1a) receptor mediation. This rightward shift by SR-49059 was significantly more in infarcted rats. The suppressed response to the agonist and enhanced sensitivity to the antagonist suggest a reduction of V(1a) receptor number in infarcted rats. In both sham and infarcted rats, the urine production after OPC-31260 (337+/-14 and 329+/-30 microl/min, respectively) was about twice of that in vehicle-treated rats (188+/-25 and 155+/-24 microl/min, respectively). However, the response in infarcted rats reached its peak quicker and lasted for a shorter period, resulting in a 40% lower area under the curve. Although only measurable during V(2) receptor blockade, the reduction of urine production by vasopressin was significantly more in infarcted compared to sham rats. The enhanced renal response to the agonist and reduced response to the antagonist suggest an increase in V(2) receptor number in infarcted rats. In conclusion, in chronically infarcted rats, vasopressin causes vasoconstriction and fluid retention through the V(1a) and V(2) receptors, respectively. Altered responses after infarction indicate a shift from V(1a) to V(2) receptors.


Subject(s)
Antidiuretic Hormone Receptor Antagonists , Blood Pressure/drug effects , Kidney/drug effects , Myocardial Infarction/physiopathology , Vasopressins/pharmacology , Animals , Benzazepines/pharmacology , Chronic Disease , Consciousness , Coronary Vessels/surgery , Dose-Response Relationship, Drug , Indoles/pharmacology , Kidney/physiopathology , Ligation/adverse effects , Male , Myocardial Infarction/etiology , Myocardial Infarction/pathology , Pyrrolidines/pharmacology , Rats , Rats, Wistar , Receptors, Vasopressin/physiology , Urination/drug effects , Urodynamics/drug effects
5.
Nucleic Acids Res ; 28(14): 2717-25, 2000 Jul 15.
Article in English | MEDLINE | ID: mdl-10908328

ABSTRACT

Several studies have shown improved efficacy of cholesteryl-conjugated phosphorothioate antisense oligodeoxynucleotides. To gain insight into the mechanisms of the improved efficacy in vivo, we investigated the disposition of ISIS-9388, the 3'-cholesterol analog of the ICAM-1-specific phosphorothioate oligodeoxynucleotide ISIS-3082, in rats. Intravenously injected [(3)H]ISIS-9388 was cleared from the circulation with a half-life of 49.9 +/- 2.2 min (ISIS-3082, 23.3 +/- 3.8 min). At 3 h after injection, the liver contained 63.7 +/- 3. 3% of the dose. Compared to ISIS-3082, the hepatic uptake of ISIS-9388 is approximately 2-fold higher. Endothelial, Kupffer and parenchymal cells accounted for 45.7 +/- 5.7, 33.0 +/- 5.9 and 21.3 +/- 2.6% of the liver uptake of [(3)H]ISIS-9388, respectively, and intracellular concentrations of approximately 2, 75 and 50 microM, respectively, could be reached in these cells (1 mg/kg dose). Preinjection with polyinosinic acid or poly-adenylic acid reduced the hepatic uptake of [(3)H]ISIS-9388, which suggests the involvement of (multiple) scavenger receptors. Size exclusion chromatography of mixtures of the oligonucleotides and rat plasma indicated that ISIS-9388 binds to a larger extent to high molecular weight proteins than ISIS-3082. Analysis by agarose gel electrophoresis indicated that ISIS-9388 binds more tightly to plasma proteins than ISIS-3082. The different interaction of the oligonucleotides with plasma proteins possibly explains their different dispositions. We conclude that cholesterol conjugation results in high accumulation of phosphorothioate oligodeoxynucleotides in various liver cell types, which is likely to be beneficial for antisense therapy of liver-associated diseases.


Subject(s)
Blood Proteins/metabolism , Cholesterol/analogs & derivatives , Cholesterol/pharmacokinetics , Liver/metabolism , Membrane Proteins , Oligodeoxyribonucleotides, Antisense/pharmacokinetics , Receptors, Lipoprotein , Thionucleotides/pharmacokinetics , Animals , Cholesterol/blood , Cholesterol/chemistry , Liver/cytology , Male , Oligodeoxyribonucleotides, Antisense/blood , Oligodeoxyribonucleotides, Antisense/chemistry , Protein Binding , Rats , Rats, Wistar , Receptors, Immunologic/metabolism , Receptors, Scavenger , Scavenger Receptors, Class B , Thionucleotides/blood , Thionucleotides/chemistry , Tritium
6.
J Cardiovasc Pharmacol ; 36(1): 38-44, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10892658

ABSTRACT

After myocardial infarction, plasma levels of [Arg8]-vasopressin rise to recover hemodynamics. The vascular responses to [Arg8]-vasopressin were studied in vitro in isolated hearts and mesenteric artery segments of rats with 1-day and 3-week-old infarcts, in absence and presence of the V1a-receptor antagonist SR-49059 and the V2-receptor antagonist OPC-31260. Vascular responses of coronary arteries were similar in sham and infarcted hearts. On average, coronary flow was maximally decreased by 70 +/- 3% from baseline values of 11.1 +/- 0.3 ml/min, with pD2 values of 10.52 +/- 0.05. In mesenteric artery segments of sham and infarcted rats, maximal contractile forces, expressed as percentage of contraction to 125 mM KCl, were similar (232 +/- 23% and 239 +/- 8%, respectively). However, pD2 values from infarcted rats (9.22 +/- 0.07) were significantly lower compared with sham (9.55 +/- 0.07) rats. In coronary as well as mesenteric vessels, the vasoconstrictor responses, being more susceptible to SR-49059 (apparent pA2, between 9.12 and 9.82) than to OPC-31260 (apparent pA2, between 6.21 and 6.92), seemed mediated by the V1a receptor. These data indicate that in mesenteric but not in coronary vessels, an altered responsiveness to vasopressin could be observed. Responses are mediated mainly by the V1a receptor.


Subject(s)
Arginine Vasopressin/pharmacology , Coronary Vessels/drug effects , Mesenteric Arteries/drug effects , Myocardial Infarction , Vasoconstrictor Agents/pharmacology , Animals , Antidiuretic Hormone Receptor Antagonists , Benzazepines/pharmacology , Benzazepines/therapeutic use , Coronary Circulation/drug effects , Coronary Circulation/physiology , Coronary Vessels/physiology , Indoles/pharmacology , Indoles/therapeutic use , Ligation , Male , Mesenteric Arteries/physiology , Myocardial Infarction/drug therapy , Myocardial Infarction/physiopathology , Pyrrolidines/pharmacology , Pyrrolidines/therapeutic use , Rats , Rats, Wistar , Receptors, Vasopressin/physiology
7.
Antimicrob Agents Chemother ; 44(3): 477-83, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10681306

ABSTRACT

Our aim is to selectively deliver 9-(2-phosphonylmethoxyethyl)adenine (PMEA) to parenchymal liver cells, the primary site of hepatitis B virus (HBV) infection. Selective delivery is necessary because PMEA, which is effective against HBV in vitro, is hardly taken up by the liver in vivo. Lactosylated reconstituted high-density lipoprotein (LacNeoHDL), a lipid particle that is specifically internalized by parenchymal liver cells via the asialoglycoprotein receptor, was used as the carrier. PMEA could be incorporated into the lipid moiety of LacNeoHDL by attaching, via an acid-labile bond, lithocholic acid-3alpha-oleate to the drug. The uptake of the lipophilic prodrug (PMEA-LO) by the liver was substantially increased after incorporation into LacNeoHDL. Thirty minutes after injection of [(3)H]PMEA-LO-loaded LacNeoHDL into rats, the liver contained 68.9% +/- 7.7% of the dose (free [(3)H]PMEA, <5%). Concomitantly, the uptake by the kidney was reduced to <2% of the dose (free [(3)H]PMEA, >45%). The hepatic uptake of PMEA-LO-loaded LacNeoHDL occurred mainly by parenchymal cells (88.5% +/- 8.2% of the hepatic uptake). Moreover, asialofetuin inhibited the liver association by >75%, indicating uptake via the asialoglycoprotein receptor. The acid-labile linkage in PMEA-LO, designed to release PMEA during lysosomal processing of the prodrug-loaded carrier, was stable at physiological pH but was hydrolyzed at lysosomal pH (half-life, 60 to 70 min). Finally, subcellular fractionation indicates that the released PMEA is translocated to the cytosol, where it is converted into its active diphosphorylated metabolite. In conclusion, lipophilic modification and incorporation of PMEA into LacNeoHDL improves the biological fate of the drug and may lead to an enhanced therapeutic efficacy against chronic hepatitis B.


Subject(s)
Adenine/analogs & derivatives , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacokinetics , Hepatitis B/drug therapy , Liver/metabolism , Organophosphonates , Adenine/administration & dosage , Adenine/blood , Adenine/chemistry , Adenine/pharmacokinetics , Animals , Antiviral Agents/blood , Antiviral Agents/chemistry , Chromatography/methods , Drug Carriers , Lipoproteins, HDL/metabolism , Lithocholic Acid/analogs & derivatives , Lithocholic Acid/chemical synthesis , Lithocholic Acid/metabolism , Lithocholic Acid/pharmacology , Liver/cytology , Liver/drug effects , Male , Prodrugs/administration & dosage , Prodrugs/chemical synthesis , Prodrugs/pharmacokinetics , Rats , Rats, Wistar , Tissue Distribution , Tritium
8.
Biochem Pharmacol ; 59(11): 1407-16, 2000 Jun 01.
Article in English | MEDLINE | ID: mdl-10751550

ABSTRACT

Low-density lipoprotein (LDL) has been proposed as carrier for the selective delivery of anticancer drugs to tumor cells. We reported earlier the association of several lipidic steroid-conjugated anticancer oligodeoxynucleotides (ODNs) with LDL. In the present study, we determined the stability of these complexes. When the complexes were incubated with a mixture of high-density lipoprotein and albumin, or with rat plasma, the oleoyl steroid-conjugated ODNs appeared to be more stably associated with LDL than the cholesteryl-conjugated ODN. Intravenously injected free lipid-ODNs were very rapidly cleared from the circulation of rats. The area under the curve (AUC) of the lipid-ODNs in plasma was <0.4 microg x min/mL. After complexation with LDL, plasma clearance of the lipid-ODNs was delayed. This was most evident for ODN-5, the ODN conjugated with the oleoyl ester of lithocholic acid (AUC = 6.82 +/- 1.34 microg x min/mL). The AUC of ODN-4, a cholesteryl-conjugated ODN, was 1.49 +/- 0.37 microg x min/mL. In addition, the liver uptake of the LDL-complexed lipid-ODNs was reduced. The lipid-ODNs were also administered as a complex with lactosylated LDL, a modified LDL particle that is selectively taken up by the liver. A high proportion of ODN-5 was transported to the liver along with lactosylated LDL (69.1 +/- 8.1% of the dose at 15 min after injection), whereas much less ODN-4 was transported (36.6 +/- 0.1% of the dose at 15 min after injection). We conclude that the oleoyl ester of lithocholic acid is a more potent lipid anchor than the other steroid lipid anchors. Because of the stable association, the oleoyl ester of lithocholic acid is an interesting candidate for tumor targeting of anticancer ODNs with lipoproteins.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Lipoproteins, LDL/pharmacokinetics , Liver/metabolism , Oligodeoxyribonucleotides, Antisense/pharmacokinetics , Steroids/pharmacokinetics , Animals , Antineoplastic Agents/blood , Humans , Lactose/metabolism , Lipoproteins, HDL/metabolism , Lipoproteins, LDL/blood , Male , Metabolic Clearance Rate , Oligodeoxyribonucleotides, Antisense/blood , Rats , Rats, Wistar , Serum Albumin/metabolism , Steroids/blood
9.
Nucleic Acids Res ; 25(16): 3290-6, 1997 Aug 15.
Article in English | MEDLINE | ID: mdl-9241243

ABSTRACT

Systemically administered phosphorothioate antisense oligodeoxynucleotides can specifically affect the expression of their target genes, which affords an exciting new strategy for therapeutic intervention. Earlier studies point to a major role of the liver in the disposition of these oligonucleotides. The aim of the present study was to identify the cell type(s) responsible for the liver uptake of phosphorothioate oligodeoxynucleotides and to examine the mechanisms involved. In our study we used ISIS-3082, a phosphorothioate antisense oligodeoxynucleotide specific for murine ICAM-1. Intravenously injected [3H]ISIS-3082 (dose: 1 mg/kg) was cleared from the circulation of rats with a half-life of 23.3+/-3.8 min. At 90 min after injection (>90% of [3H]ISIS-3082 cleared), the liver contained the most radioactivity, whereas the second-highest amount was recovered in the kidneys (40.5+/-1.4% and 17.9+/-1.3% of the dose, respectively). Of the remaining tissues, only spleen and bone marrow actively accumulated [3H]ISIS-3082. By injecting different doses of [3H]ISIS-3082, it was found that uptake by liver, spleen, bone marrow, and kidneys is saturable, which points to a receptor-mediated process. Subcellular fractionation of the liver indicates that ISIS-3082 is internalized and delivered to the lysosomes. Liver uptake occurs mainly (for 56.1+/-3.0%) by endothelial cells, whereas parenchymal and Kupffer cells account for 39.6+/-4.5 and 4.3+/-1.7% of the total liver uptake, respectively. Preinjection of polyinosinic acid substantially reduced uptake by liver and bone marrow, whereas polyadenylic acid was ineffective, which indicates that in these tissues scavenger receptors are involved in uptake. Polyadenylic acid, but not polyinosinic acid, reduced uptake by kidneys, which suggests renal uptake by scavenger receptors different from those in the liver. We conclude that scavenger receptors on rat liver endothelial cells play a predominant role in the plasma clearance of ISIS-3082. As scavenger receptors are also expressed on human endothelial liver cells, our findings are probably highly relevant for the therapeutic application of phosphorothioate oligodeoxynucleotides in humans. If the target gene is not localized in endothelial liver cells, the therapeutic effectiveness might be improved by developing delivery strategies that redirect the oligonucleotides to the actual target cells.


Subject(s)
Liver/metabolism , Membrane Proteins , Oligonucleotides, Antisense/metabolism , Receptors, Immunologic/metabolism , Receptors, Lipoprotein , Thionucleotides/metabolism , Animals , Endothelium/metabolism , Intercellular Adhesion Molecule-1/genetics , Male , Metabolic Clearance Rate , Mice , Polyelectrolytes , Polymers/metabolism , Rats , Rats, Wistar , Receptors, Scavenger , Scavenger Receptors, Class B , Subcellular Fractions/metabolism , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...